Catalyst Biosciences Inc

-0.02 (-1.74%)
Earnings Announcements

Catalyst Biosciences Q3 Loss Per Share $0.80

Published: 11/12/2021 12:47 GMT
Catalyst Biosciences Inc (CBIO) - Q3 Loss per Share $ to Discontinue Marzaa Development; Focus on Developing Its Complement Portfolio.
Announces Change in Corporate Strategy.
Exploring Opportunities to License Or Sell Our Marzaa and Dalca (engineered Fix) Portfolios.
Halting Development of Marzaa Will Allow US to Reduce Our Burn Rate by Approximately 40%.
Catalyst Biosciences - Enrollment in Marzaa Clinical Trials Adversely Impacted by Several Factors; No Longer Feasible to Deliver Topline Data in 2022.
Will Advance Clinical Development of Cb 4332, an Sq-dosed Enhanced Complement Factor I (cfi), As Swiftly As Possible.
Revenue is expected to be $0.17 Million
Adjusted EPS is expected to be -$0.59

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.49

More details on our Analysts Page.